# This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

> **NCT00517218** · PHASE3 · WITHDRAWN · sponsor: **Genta Incorporated**

## Conditions studied

- Lymphocytic Leukemia

## Interventions

- **DRUG:** Genasense® (, oblimersen sodium G3139)

## Key facts

- **NCT ID:** NCT00517218
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2009-06
- **Target enrollment:** — (—)
- **Last updated:** 2008-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517218, "This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00517218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*